logo-loader

PharmaDrug subsidiary adds drug repurposement expert Moshe Rogosnitzky to its scientific and clinical advisory board

Published: 09:36 09 Mar 2021 EST

Pills in packaging
Rogosnitzky has more than 15 years of experience in the use of Cepharanthine for treating advanced cancers, as well as androgenic alopecia

PharmaDrug Inc (CSE:BUZZ) (OTCPINK:LMLLF) subsidiary Sairiyo Therapeutics Inc, a biotechnology company developing Cepharanthine, a repurposed naturally-derived compound for the potential treatment of cancer and other diseases, announced Tuesday that drug-repurposing expert Moshe Rogosnitzky has joined its newly-formed scientific and clinical advisory board. 

Rogosnitzky leads Drug Rediscovery Group Ltd in Rehovot, Israel, which focuses on the repurposing of generic drugs for diseases, including ophthalmic disorders, viral infections, insomnia, pain disorders and opioid addiction. He also serves as executive director of the MedInsight Institute, a US/Israel non-profit organization that educates physicians and patients about treatment opportunities using generic drugs in an off-label fashion. 

Rogosnitzky has more than 15 years of experience in the use of Cepharanthine for treating advanced cancers, as well as androgenic alopecia, or male-pattern baldness. In 2011, he published a comprehensive review on the potential of Cepharanthine for a range of clinical conditions, including as a treatment for COVID-19. 

READ: PharmaDrug welcomes top Memorial Sloan Kettering gastrointestinal oncologist Yelena Janjigian to its scientific and clinical advisory board

"I am passionate about repurposing safe and well-established drugs for treating cancer, whether alone or as adjuvants to existing therapies,” Rogosnitzky said in a statement. “Cepharanthine presents a unique opportunity to repurpose an extremely safe drug that has been approved and used in Japan for other clinical indications for many years. It is my hope that this plant-derived drug, possessing an enviable safety record, will provide fresh hope to patients suffering from incurable cancers and other serious and life-threatening diseases."

Cepharanthine is a natural product and an approved drug used for more than 70 years in Japan to treat a variety of acute and chronic diseases. In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, antiviral and antiparasitic properties.

"We are grateful to have Moshe Rogosnitzky join us as an advisor to support our development plans with Cepharanthine, which has tremendous potential in not only cancer but also in other serious and rare diseases," PharmaDrug CEO Daniel Cohen said. "Moshe Rogosnitzky has an in-depth knowledge and appreciation for Cepharanthine's potential and him joining our scientific and clinical advisory board dedicated to unlocking Cepharanthine's clinical utility for cancers and other indications brings value to our objective in developing a unique franchise with Cepharanthine."

Sairiyo has an exclusive license from a research and development organization to develop and commercialize reformulated Cepharanthine for all diseases and exclusive rights to the patent, method of manufacturing, clinical supply, pre-clinical data and know-how to support FDA clinical trials. The company recently received FDA orphan drug designation for Cepharanthine in the treatment of esophageal cancer.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Pharmadrug CEO says completion of cGMP substance manufacturing advances its...

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen joined Proactive's Stephen Gunnion with the news that the company has completed cGMP (good manufacturing practices) production of a multi-kilogram batch of cepharanthine-2HCl, a key ingredient in PD-001, the oral version of...

on 10/04/2022